HER2/neu Overexpression and Recurrence Risk in Early Stage Uterine Serous Carcinoma

被引：0
|
作者：
Blakaj, A. [1 ]
Jairam, V. [2 ]
Buza, N. [3 ]
Schwartz, P. [4 ]
Santin, A. [4 ]
Damast, S. [1 ]
机构：
[1] Yale Sch Med, Dept Therapeut Radiol, New Haven, CT USA
[2] Yale Sch Med, New Haven, CT USA
[3] Yale Sch Med, Dept Pathol, New Haven, CT USA
[4] Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2018年 / 102卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2018.07.139
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1126
引用
收藏
页码：S218 / S219
页数：2
相关论文
共 50 条
  • [31] HER2 Testing in Uterine Serous Carcinoma: Comparison of Two Criteria
    Zhang, Gloria
    Sciallis, Andrew
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1275 - S1276
  • [32] FOLR1 and HER2 Expression in Uterine Serous Carcinoma
    Finkelman, Brian
    Tyburski, Haley
    Mendoza, Rachelle
    Zhang, Huina
    Sanchez, Janira Navarro
    Varghese, Sharlin
    Wang, Xi
    Katerji, Hani
    Schiffhauer, Linda
    Chen, Jack
    Hicks, David
    Turner, Bradley
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1147 - S1148
  • [33] Overxpression of HER2/neu in uterine carcinosarcoma
    Nishikawa, T.
    Yonemori, K.
    Okuma, H.
    Kawachi, A.
    Kitano, A.
    Shimoi, T.
    Shimomura, A.
    Noguchi, E.
    Yunokawa, M.
    Yoshida, H.
    Shimizu, C.
    Fujiwara, Y.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study
    Erickson, Britt K.
    Najjar, Omar
    Damast, Shari
    Blakaj, Adriana
    Tymon-Rosario, Joan
    Shahi, Maryam
    Santin, Alessandro
    Klein, Molly
    Dolan, Michelle
    Cimino-Mathews, Ashley
    Buza, Natalia
    Ferriss, J. Stuart
    Stone, Rebecca L.
    Khalifa, Mahmoud
    Fader, Amanda N.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 17 - 22
  • [35] Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort.
    Erickson, Britt Kristina
    Najjar, Omar
    Klein, Molly
    Shahi, Maryam
    Dolan, Michelle
    Cimino-Mathews, Ashley
    Grandelis, Anthony
    Buza, Natalia
    Delaney, Paris
    Tymon-Rosario, Joan
    Santin, Alessandro
    Ferriss, James Stuart
    Stone, Rebecca Lynn
    Fader, Amanda Nickles
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization
    Santin, AD
    Bellone, S
    Van Stedum, S
    Bushen, W
    De Las Casas, LE
    Korourian, S
    Tian, E
    Roman, JJ
    Burnett, A
    Pecorelli, S
    GYNECOLOGIC ONCOLOGY, 2005, 98 (01) : 24 - 30
  • [37] Commenting on "HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? (88:263-5) by Santin AD"
    Slomovitz, BM
    Lu, KH
    GYNECOLOGIC ONCOLOGY, 2004, 92 (01) : 386 - 387
  • [38] Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu
    Tymon-Rosario, Joan
    Siegel, Eric R.
    Bellone, Stefania
    Harold, Justin
    Adjei, Naomi
    Zeybek, Burak
    Mauricio, Dennis
    Altwerger, Gary
    Menderes, Gulden
    Ratner, Elena
    Clark, Mitchell
    Andikyan, Vaagn
    Huang, Gloria S.
    Azodi, Masoud
    Schwartz, Peter E.
    Fader, Amanda N.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2021, 163 (01) : 93 - 99
  • [39] Overexpression of HER2/neu oncoprotein in cytologic specimens
    Mitteldorf, CATS
    Leite, KRM
    Meirelles, MI
    Gattas, GJF
    Camara-Lopes, LH
    ACTA CYTOLOGICA, 2004, 48 (02) : 199 - 206
  • [40] HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy
    Klc, Tenley R.
    Wu, Sharon
    Wilhite, Annelise M.
    Jones, Nathaniel L.
    Powell, Matthew A.
    Olawaiye, Alex
    Girda, Eugenia
    Brown, Jubilee
    Puechl, Allison
    Ali-Fehmi, Rouba
    Winer, Ira S.
    Herzog, Thomas J.
    Korn, W. Michael
    Erickson, Britt K.
    GYNECOLOGIC ONCOLOGY, 2022, 167 (02) : 289 - 294
12345